Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

VannaBlack Sep. 21 at 6:05 PM

$SPMO nope after momentum rebalance im selling, 50%+ is in direct AI trades still. 8 out of the top 10. They also counted $GOOG and $GOOGL separately, lol. The only 2 that weren't AI were $JNJ and $XOM Still too top heavy and the risk is off the charts because if the Anthropic IPO goes poorly, goodnight.

1 · Reply

LibertarianTreehugger Sep. 21 at 4:56 PM

J&J’s Caplyta Shows Promise Against Bipolar Mania: https://jlsfund.substack.com/p/j-and-js-caplyta-shows-promise-against $JNJ

0 · Reply

Techdamentals Sep. 21 at 4:28 PM

$JNJ Defensive money ran here last week. This morning it's rotating back toward growth. What's it worth? 👇 https://techdamentals.com/v/JNJ Educational, not advice.

0 · Reply

focafoca99 Sep. 21 at 12:20 PM

$JNJ shared positive Phase 3 results for CAPLYTA in bipolar mania, meeting primary endpoint with rapid improvement by Day 3. https://www.rapidticker.com/news/jnj-caplyta-lumateperone-shows-significant-and-1ec78e

0 · Reply

jamesmckevitt Sep. 21 at 8:42 AM

$SLS morning all ☕️ just a quick reminder of where we are for any new/current/potential investors: Science/Products: REGAL at 78 out of 80 events, Ad infinium dosing, meaning patients are being treated for 3 years and beyond, Little to no toxicity reported in comparison to BAT, GPS mOS well surpassing BAT in its current stage. Management/Directors Sterg is limited by what he can say, but seems increasingly comfortable, Not one insider have sold any shares, Katherine Bach Kalin on the board, she was part of the board of $CELG that got purchased by $BMY for 74b. Financials: 138.5m as a cash for a runaway for years, Under 1m in debt, Cash burn is minimal. Speculation: Product Director at $JNJ calling GPS a ‘game changer’ and has been studying it for a year and a half, $AZN senior executive praising GPS and stating it’s also a ‘game changer’ Medical industries executives stating GPS is a ‘block buster’

0 · Reply

OldManGrumble Sep. 19 at 10:55 PM

$JNJ

0 · Reply

jhk35611 Sep. 19 at 9:26 PM

$SLS $JNJ merger any day now? 1 share of $$JNJ for 1.5 shares of $SLS ? A $35B valuation for $SLS. So many hints snd implied connections in last 6 months. And a huge BP like $JNJ could quickly take the 20 cancer WT1 platform through trials and FDA approvals as well as maximize SLS009 and the little talked about GPS+ peptide vaccine. Would certainly give hope to cancer patients all over the world. 😎❤️🙏 May it come to pass.

2 · Reply

peloswing Sep. 19 at 3:33 AM

$PEP Pepsi with an ugly break of support today and on its way to fill the gap from July 2025 next ($128.82) 🥤 - Now down >22% from the February highs - Just elected the $JNJ CEO to its board

1 · Reply

Outcomes Sep. 19 at 12:50 AM

$IBRX $JNJ $MRK $MRNA $PFE mRNA BAD. https://x.com/nichulscher/status/2101050193491669325?s=46

2 · Reply

Outcomes Sep. 18 at 11:25 PM

$IBRX $MRNA $MRK $PFE $JNJ mRNA BAD. ‘Turbo-Cancers’ ALL PLANNED. NEVER FORGET! SAVE THE CHILDREN 🙏🏻 PSS KNOWS. Dr. Jim Kim knows RFK Jr. knows Dr. Jay B knows https://x.com/c__herridge/status/2101069201670881433?s=46

3 · Reply

Market Cap	650.65B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	24.86
Forward PE	23.26
Profit Margin	28.46%
Debt to Equity Ratio	0.44

Volume	4,487,464
Avg Vol	7,119,228
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	81%
Beta	0.24
Analysts	Strong Sell
Price Target	$281.24